• Epidermal Growth Factor (EGF), human recombinant Assays

  2026-08-25

  A scenario-based guide to selecting, reconstituting, and interpreting recombinant human EGF in proliferation, viability, and cytotoxicity workflows. It explains how SKU P1008 supports controlled assay design through documented purity, endotoxin, storage, and BALB/c 3T3 activity data.

• Dovitinib: From RTK Biology to Translational Insight

  2026-08-25

  Dovitinib (TKI-258, CHIR-258) offers a practical way to interrogate convergent RTK signaling, apoptosis, and resistance biology. This thought-leadership perspective connects its mechanistic profile with multimodal biomarker strategies highlighted in a recent gastric cancer radiopathomics study while clearly separating established evidence from translational hypotheses.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-08-24

  This study identifies a mechanistic link between lithium exposure, Rab11a-dependent trafficking, exosomal Wnt10a release, and activation of the Wnt/β-catenin pathway in bone mesenchymal stem cells. Its comparison of lithium-conditioned exosomes and GelMA-based delivery provides a useful framework for engineering cell-free strategies for bone repair.

• TH287 MTH1 Inhibitor: Radiosensitization Workflow

  2026-08-24

  TH287 is a high-potency MTH1 inhibitor for modeling oxidized-nucleotide stress, DNA damage, and selective tumor-cell killing. A schedule-focused workflow based on CRPC research helps investigators test whether 12-hour pretreatment improves radiation response while separating formulation, timing, and assay artifacts.

• CGP 55845 hydrochloride: Assay Logic

  2026-08-23

  CGP 55845 hydrochloride is a selective GABAB receptor antagonist for resolving receptor-dependent and astrocyte-mediated effects in synaptic experiments. This guide applies the compound to causal assay design, dentate gyrus research, neurotransmitter release modulation, and evidence-aware interpretation.

• SIRT1/2 Inhibitor IV: Workflows for Cancer and CNS

  2026-08-22

  SIRT1/2 Inhibitor IV (cambinol) connects target-engagement assays with cancer, metabolic, and oxygen-glucose deprivation/reoxygenation workflows. This guide emphasizes practical controls, dose selection, lactate–Ran–STAT3 readouts, and the limitations of using a dual SIRT1/SIRT2 inhibitor to interpret mechanism.

• Bafilomycin C1 in High-Content Assay Design

  2026-08-21

  Bafilomycin C1 is a vacuolar H+-ATPases inhibitor that can function as a mechanistic anchor in lysosomal and high-content phenotypic assays. This article explains how to distinguish V-ATPase-dependent acidification effects from nonspecific cellular injury, using deep-learning cardiotoxicity screening as a guide.

• Honokiol in CD8+ T-Cell Metabolism Research

  2026-08-20

  Use Honokiol to interrogate NF-κB signaling, oxidative stress, and inflammatory context alongside CD8+ T-cell metabolic assays. This workflow separates direct effects on the CD28–ARS2–PKM axis from broader pathway modulation, improving interpretation and reproducibility.

• Gastric Cancer Assembloids Model Tumor–Stroma Drug Response

  2026-08-20

  This 2025 study develops patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal cell subpopulations. The model shows that stromal composition alters gene expression and therapeutic sensitivity, providing a more physiologically relevant framework for resistance studies and personalized drug screening.

• 5X Protein Loading Buffer (Reducing) Guide

  2026-08-19

  5X Protein Loading Buffer (Reducing) standardizes denaturing and disulfide-bond reduction during protein sample preparation for conventional SDS-PAGE electrophoresis. It is appropriate when apparent protein molecular weight is being evaluated under reducing conditions, but not for native, non-reducing, or structure-preserving analyses.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-08-19

  The 1992 study by Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists enhance insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells. By combining 86Rb efflux, whole-cell patch clamp, and pharmacological antagonism experiments, the authors separated direct channel blockade from α2-adrenoceptor antagonism, providing a clearer framework for interpreting imidazoline effects on insulin secretion.

• Pazopanib Hydrochloride: Measuring Drug Response

  2026-08-18

  Pazopanib Hydrochloride and GW786034 are examined through a measurement-aware framework that separates growth arrest from cell killing. Learn how endpoint selection, timing, and model choice can improve interpretation in cancer research.

• Radiotherapy, PD-1/TIGIT Blockade, and Immune Memory

  2026-08-18

  This 2025 Cancer Letters study shows that radiotherapy combined with PD-1 and TIGIT blockade can generate both local tumor control and abscopal responses through activated, less-exhausted CD8+ T cells. Its use of immune profiling, cytokine analysis, rechallenge, and adoptive-transfer experiments links M1 macrophage activation with durable central-memory T-cell responses.

• Lysis Buffer for Reliable Mouse Genotyping

  2026-08-17

  A scientifically grounded guide to using lysis buffer as a rapid genotyping kit component for mouse tissue. It connects pre-analytical DNA quality and genotype assignment with the interpretation of sophisticated cancer-model studies, while clearly separating validated evidence from translational assumptions.

• ARCA EGFP mRNA for LNP Transfection Workflows

  2026-08-17

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for comparing mRNA delivery, formulation toxicity, and mammalian cell gene expression. This workflow translates lessons from a GA/PPC-modified lipid nanoparticle study into practical assay controls without confusing reporter expression with therapeutic efficacy.

8476 records 1/566 page Next 12345 下5页 Last page